Alnylam Pharmace. buy BMO Capital Markets
Start price
27.03.24
/
50%
€141.40
Target price
27.03.25
€216.31
Performance (%)
-5.30%
Price
25.04.24
€133.90
Summary
This prediction is currently active. With a performance of -5.30%, the BUY prediction for Alnylam Pharmace. by BMO_Capital_Markets is down slightly. This prediction currently runs until 27.03.25. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -1.217% | -1.217% |
| iShares Core DAX® | 2.594% | -1.158% |
| iShares Nasdaq 100 | 3.553% | -1.727% |
| iShares Nikkei 225® | 0.687% | -8.354% |
| iShares S&P 500 | 2.209% | -0.942% |
Comments by BMO_Capital_Markets for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $234.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat